We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Industry Protests Higher Fees at Brazil’s ANVISA

Industry Protests Higher Fees at Brazil’s ANVISA

September 11, 2015

Brazil’s Agência Nacional de Vigilância Sanitária is facing criticism from the medical device industry for hiking surveillance inspection fees as the country faces tough economic times.

ANVISA maintains the fee increase — the first in the regulator’s 16-year history — is not a tax, but a restoration of purchasing power established by the nation’s legislature that had depreciated over time, but device groups disagree.

Brazilian industry group ABIMO says devicemakers are making strides and developing innovative, cost-effective products, despite the adverse economic environment, and is examining legal action.

Under the new fee scheme, a good manufacturing practices certificate for companies in Brazil or Southern Common Market member countries will jump from about U.S. $3,900 to more than $11,000 for the biggest firms. Foreign manufacturers face an even greater increase — from $9,684 to more than $28,000 — irrespective of size. The new fees took effect Sept. 9. Manufacturers that didn’t meet the Sept. 8 deadline to pay the old fees must pay the difference.

A document on the ANVISA website details the fees, breaking them down for microenterprises, small companies, medium and large companies.

Roberto Rodrigues, an attorney at Licks Legal, says the fees affect a range of regulated industries and could bring in as much as $350 million.

A technical note explaining the fees is available here: www.fdanews.com/091515-anvisa.pdf. The document breaking down the fees is available at www.fdanews.com/091515-ANVISA-fees.pdf. — Elizabeth Hollis, Jonathon Shacat.

Regulatory Affairs

Upcoming Events

  • 10Mar

    FDA Drug GMP Facility Inspections During the Pandemic

  • 16Mar

    Pharmaceutical Naming Regulation: Understanding the Latest Developments

  • 18Mar

    Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

  • 06Apr

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • Vaccine needle

    Turkish Researchers Downgrade Sinovac’s COVID-19 Vaccine Efficacy Rate

  • Luminex logo

    Luminex Receives EUA for Expanded Respiratory Pathogen Panel, Clearing It for COVID-19

  • Acquires -Acquired

    Amgen to Buy Five Prime Therapeutics for $1.9 Billion

  • abbott-logo.gif

    Abbott Secures EUA for COVID-19 Combination Test

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing